About this item:

259 Views | 74 Downloads

Author Notes:

Correspondence: C. S. Kraft, Emory University Hospital, Department of Pathology and Laboratory Medicine, 1364 Clifton Rd NE, F145C, Atlanta, GA 30322 (colleen.kraft@emory.edu).

V. N. R., G. K., C. S. K., and T. W. contributed equally to this work.

Members of the Emory Serious Communicable Diseases Unit are listed after the References.

See publication for full list of author contributions.

We thank Sarah Katharina Fehling and Svenja Wolff for virus isolation work and Michael Schmidt and Gotthard Ludwig for technical support in the biosafety level 4 facility at the Philipps University of Marburg.

We express our gratitude to the nursing staff of the intensive care pool and the Infectious Diseases Department, University Hospital Frankfurt.

We thank Debi Cannon, Cheng-Feng Chiang, William Davis, Aridth Gibbons, James Graziano, Mary Jenks, Maria Morales-Betouille and Nishi Patel for their assistance in performance of the laboratory testing at the Centers for Disease Control and Prevention (CDC).

We are appreciative of the support of the US Food and Drug Administration, Valeant, and Medivector for the provision of the therapeutics for these patients.

We thank the Investigational Drug Service at Emory University and the Emory University Institutional Review Board.

See publication for full list of disclosures.

Subjects:

Keywords:

  • Science & Technology
  • Life Sciences & Biomedicine
  • Immunology
  • Infectious Diseases
  • Microbiology
  • Lassa
  • favipiravir
  • ribavirin
  • Togo
  • EBOLA-VIRUS
  • PERSISTENCE
  • LETHAL

Favipiravir and Ribavirin Treatment of Epidemiologically Linked Cases of Lassa Fever

Show all authors Show less authors

Journal Title:

Clinical Infectious Diseases

Volume:

Volume 65, Number 5

Publisher:

, Pages 855-859

Type of Work:

Article | Post-print: After Peer Review

Abstract:

Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. Two patients with Lassa fever are described who are the first human cases treated with a combination of ribavirin and favipiravir. Both patients survived but developed transaminitis and had prolonged detectable virus RNA in blood and semen, suggesting that the possibility of sexual transmission of Lassa virus should be considered.

Copyright information:

© Author 2017.

Export to EndNote